Gatsky

5 ms·

1.
by Gatsky 3y ago
Read the ESR1 rapid update. The methods say: "A targeted electronic literature search was conducted to identify any additional phase III randomized controlled trials in this patient population. No additional randomized controlled trial
2.
by Gatsky 3y ago
Sorry to hear you have suffered poor quality interactions with doctors. Being honest, if there is no trust in the relationship between patient and doctor, then nothing else matters much as the experience will be poor on both sides. Patient
3.
by Gatsky 3y ago
Actually doctors would be universally happy to get more help and support to deliver better healthcare. That you don't talk about that is quite telling, or is that what you mean by 'regulation'? Casting the patient doctor rela
4.
by Gatsky 3y ago
I don't think it is false. I can only speak of my experience as an oncology healthcare provider. I spend many hours each week digesting the literature, and <5% of that involves meta-analyses. In the multidisciplinary meetings I chai
5.
by Gatsky 3y ago
The president of Medicens sans frontieres, Rowan Gillies, gave a speech once. He had a drawing of a patient and the doctor inside a circle. His comment was 'Other people keep trying to climb into this circle. They can all fuck off.&#x2
6.
by Gatsky 3y ago
Well you discount the most important thing in the first line. 'Cutting-edge' is a funny way of saying 'most effective', as if it were somehow irrelevant. I didn't say most evidence is from phase III RCTs, particul
7.
by Gatsky 3y ago
Disagree. I change practice on Monday after a single quality trial. Pick up any society guideline, only a small amount of the recommendations rely on meta-analyses. Look at immunotherapy or antibody drug conjugates, revolutionary therapies
8.
by Gatsky 3y ago
Yeah, well in my field, oncology, meta-analyses are somewhat irrelevant. As you can imagine, the bar for completing a phase 3 randomised trial in oncology is pretty high. Meta-analyses are mostly there for trainees to notch up a paper. Anot
9.
by Gatsky 3y ago
IRBs do not evaluate the value of a research endeavour. They are in fact unable to do this due to lack of knowledge and expertise. They approve trials which fit the mold of trials they have seen before. Why does a clinical trial get done? T
10.
by Gatsky 3y ago
The biggest issue, IMHO, is that clinical trials are often unethical. This is both in theory and especially in practice. I say this as a physician and clinical trial investigator. EBM deals with this by saying ‘there is no viable alternativ
11.
by Gatsky 3y ago
Some people aren't worth it. Some people are just miserable. Not depressed, just miserable. Some people are insecure, vindictive, manipulative, querulous, disagreeable. Having a relationship with them will be as much as 100x more diffi
12.
by Gatsky 3y ago
Antivirals probably won’t help as most infections are silent, a vaccine is needed. Moderna is working on one.
13.
by Gatsky 3y ago
I think this is a great comment, with much broader implications for living well. Unmooring the sense of self from external factors is one important aspect of spirituality.
14.
by Gatsky 3y ago
This reference [1] tends to support what you are saying: > For this thesis, an atmospheric propagation code named ANCHOR (Atmospheric NPS Code for High Energy Laser Optical pRopagation) was developed and utilized to study the propagation
15.
by Gatsky 3y ago
There are thousands of sequenced human genomes available to access for research purposes (1000 genomes project, UK biobank etc) so one additional genome adds no marginal value.
16.
by Gatsky 3y ago
Re WGS there are a lot of well established tool chains that are FLOSS (eg https://github.com/bcbio/bcbio-nextgen ). You could run alignment and variant calling on a beefy workstation. A laptop would potentially work. Ea
17.
by Gatsky 3y ago
Such as? I’ve worked in genomics labs, they would be quite happy to delete stuff.
18.
by Gatsky 3y ago
Yes, find a local sequencing provider and arrange to do a SNP chip or whole genome sequencing. In the contract ask that they delete your data after delivering it to you. This will be: 1. Expensive - probably at least 2 - 3 thousand dollars.
19.
by Gatsky 3y ago
> Viewers will be able to "order up" films—for example, "I want a film about a panda and a unicorn who save the world in a rocket ship. And put Bill Murray in it." > From there I believe viewers will be given the a
20.
by Gatsky 3y ago
Although quite uncharitable, I can believe this has some truth to it. She underwent a visible transformation for the trial, wearing her hair down and changing her entire mien. Quite a contrast to her appearance during the Theranos years.
21.
by Gatsky 3y ago
I feel that alignment is not just hard but impossible, at least if you want something truly useful. Maybe the only thing you can do is let an AI develop and observe its nature from a distance, say in a simulated world running at high speed
22.
by Gatsky 3y ago
Reading this makes you realise how much of what makes Seinfeld good is in the skillful delivery. I wonder how much they would have to rehearse to get it spot on.
23.
by Gatsky 3y ago
The NYT death announcements have this tone. It says at the bottom that a formal obituary will be forthcoming.
24.
by Gatsky 3y ago
Very interesting. The increase in Coeliac disease will mostly be due to the advent of a useful blood test to detect it. The lack of association between other autoimmune diseases and multiple sclerosis fits with the recent identification of
25.
by Gatsky 3y ago
Yeah this doesn’t quite sit right. It lacks any detail about what Google is actually doing.
26.
by Gatsky 3y ago
Just came to say that this is a wonderful comment, and that people voluntarily playing with/remixing your creation is one sign of great art.
27.
by Gatsky 3y ago
A technical feat, strengthening the notion that ageing is not inevitable. At the same time, I don’t think it is particularly controversial to say that if we start modifying our own genetics we could eliminate most diseases, including many a
28.
by Gatsky 3y ago
The point still stands, there are thousands of papers demonstrating preclinical utility of nanoparticles for many applications, and extremely few actual medicines.
29.
by Gatsky 3y ago
I was listening to a talk from a leading nanoparticle researcher. He basically said that making new nanoparticles and characterising them is great for writing papers but they all fail actual testing as therapeutic delivery devices. In oncol
30.
by Gatsky 3y ago
My thoughts about this are that youtube is great if you have a specific learning task/interest, but if you don’t then it will lead you astray. There is no doubt however that it has pulled off the magic trick of incentivizing thoughtful

More ›